The Use of DPP-4 Inhibitors in Short Bowel Syndrome

• Status: Terminated
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanley Dudrick's Memorial Hospital
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months

• stable metabolic status

• benign disease

Exclusion Criteria:

• HPN < 12 months

• metabolically unstable

• cancer as the reason for intestinal failure